Welcome to our dedicated page for Ironwood SEC filings (Ticker: IRWD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ironwood Pharmaceuticals, Inc. filings document a Nasdaq-listed biotechnology company focused on gastrointestinal and rare disease therapies. Its Form 8-K reports include operating and financial results, business updates for LINZESS and apraglutide, regulatory and pricing matters involving LINZESS, and financing-related disclosures tied to credit agreements and liquidity conditions.
Proxy filings cover board elections, executive compensation votes, equity incentive plan matters, auditor ratification, and annual meeting procedures. Other filings address governance changes, Nasdaq listing-compliance matters for its Class A common stock, and the registered security structure of IRWD shares on the Nasdaq Global Select Market.
Ironwood Pharmaceuticals SVP and CMO Michael Shetzline reported automatic share sales to cover taxes on vesting restricted stock units. On Class A Common Stock and Common Stock, he sold a total of 32,582 shares in open-market transactions at weighted average prices around $3.81 and $3.66 per share. These sales were executed solely to satisfy tax withholding obligations and were not discretionary trades, and he continued to hold 521,425 shares afterward.
IRONWOOD PHARMACEUTICALS INC Chief Commercial Officer Tammi L. Gaskins reported automatic sales of Class A common stock to cover taxes on vesting restricted stock units. She sold 10,287 shares on February 23 at a weighted average price of $3.81 and 11,239 shares on February 24 at a weighted average price of $3.66, in open-market transactions. The filing states these were mandatory “sell to cover” transactions for tax withholding and not discretionary trades. After these sales, she held 213,738 shares of Ironwood common stock directly.
Ironwood Pharmaceuticals Chief Executive Officer Thomas A. McCourt reported automatic sales of Class A Common Stock to cover tax withholding from vested restricted stock units. On February 23 and 24, 2026, a total of 198,283 shares were sold in open-market transactions classified as non-derivative sales.
The filing notes these were sell-to-cover transactions executed automatically to satisfy tax obligations and did not represent discretionary trades by McCourt. Weighted average sale prices were reported, with shares on one day sold between $3.70 and $4.05 and on the other between $3.60 and $3.73. Following the February 24 sale, he directly held 1,489,002 shares. A footnote also records his acquisition of 4 shares under the company’s employee stock purchase plan on December 31, 2025.
IRONWOOD PHARMACEUTICALS INC Chief Financial Officer Gregory S. Martini reported automatic stock sales to cover taxes tied to restricted stock vesting. On February 23, he sold 10,487 shares of Class A common stock at a weighted-average price of $3.81 per share in open-market transactions within a $3.70–$4.05 range. On February 24, he sold an additional 11,457 shares at a weighted-average price of $3.66 per share within a $3.60–$3.73 range. The filing states these sales were executed automatically solely to satisfy tax withholding obligations and were not discretionary trades. After these transactions, Martini directly owned 160,601 shares of Ironwood Class A common stock.
IRONWOOD PHARMACEUTICALS INC principal accounting officer Ronald Silver reported automatic sales of 24,173 Class A common shares to cover tax withholding obligations from vesting restricted stock units. The transactions involved 11,552 shares on February 23, 2026 at a weighted average price of $3.81 and 12,621 shares on February 24, 2026 at a weighted average price of $3.66. The prices reflect multiple trades within disclosed ranges. After these tax-related, non-discretionary sales, Silver directly held 252,636 shares of Ironwood Pharmaceuticals common stock.
Ironwood Pharmaceuticals reported fourth-quarter and full-year 2025 results and reaffirmed a strong 2026 outlook. For 2025, total revenue was $296.2M, GAAP net income was $24.0M and adjusted EBITDA reached $138.1M. The company generated $127M in operating cash flow and ended the year with $215.5M in cash and cash equivalents.
LINZESS delivered 11% full-year EUTRx demand growth, remaining the leading U.S. prescription brand for IBS-C and CIC. For 2026, Ironwood expects U.S. LINZESS net sales of $1.125–$1.175B, total revenue of $450–$475M and adjusted EBITDA of more than $300M, while it advances the apraglutide Phase 3 STARS-2 trial in short bowel syndrome with intestinal failure.
Ironwood Pharmaceuticals reported proposed sales of Class A Common Stock on a Form 144, listing multiple blocks of shares tied to restricted stock unit awards. The notice lists amounts including 27,780; 8,905; 8,485; and 6,825 shares associated with RSU awards dated 02/24/2022, 02/23/2023, 02/22/2024, and 01/27/2025.
The entries state each lot is a "Restricted Stock Unit award granted pursuant to the Issuer's 2019 Equity Incentive Plan" (or amended plan) and are shown with vesting requirements. The filing is a routine Rule 144 notice of proposed resale activity and does not disclose sale prices, purchasers, or final transaction timing.
Ironwood Pharmaceuticals reported a proposed sale of Class A common stock under a Form 144 notice, identifying shares derived from multiple restricted stock unit awards. The filing lists awards dated 02/24/2022 (4,244 shares), 04/01/2022 (7,500), 02/23/2023 (8,905), 02/22/2024 (6,825), and 01/27/2025 (27,778).
Ironwood Pharmaceuticals, Inc. submitted a Form 144 notice reporting proposed sales of Class A Common Stock tied to previously granted restricted stock unit awards. The excerpt lists example lots of 20,362, 17,467, 13,606, and 33,334 shares associated with award grant dates from 03/02/2022 through 02/10/2025.
Ironwood Pharmaceuticals, Inc. submitted a Form 144 proposing resale of Class A common stock derived from restricted stock unit awards. The filing lists grant-dated lots of shares awarded on 03/02/2022, 03/08/2023, 02/12/2024, and 02/10/2025.
The excerpt includes per-lot quantities, including 16,969 and 16,375 shares as examples; these lots are described as restricted stock unit awards under the company's equity incentive plan. Timing and aggregate resale proceeds are not provided in the excerpt.